Literature DB >> 25679434

Immune intervention for type 1 diabetes, 2013-2014.

Jay S Skyler1.   

Abstract

Entities:  

Year:  2015        PMID： 25679434      PMCID： PMC4333515          DOI： 10.1089/dia.2015.1510

Source DB:  PubMed          Journal:  Diabetes Technol Ther        ISSN： 1520-9156            Impact factor:   6.118


× No keyword cloud information.
  5 in total

1.  Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes.

Authors:  Bart Keymeulen; Evy Vandemeulebroucke; Anette G Ziegler; Chantal Mathieu; Leonard Kaufman; Geoff Hale; Frans Gorus; Michel Goldman; Markus Walter; Sophie Candon; Liliane Schandene; Laurent Crenier; Christophe De Block; Jean-Marie Seigneurin; Pieter De Pauw; Denis Pierard; Ilse Weets; Peppy Rebello; Pru Bird; Eleanor Berrie; Mark Frewin; Herman Waldmann; Jean-François Bach; Daniel Pipeleers; Lucienne Chatenoud
Journal:  N Engl J Med       Date:  2005-06-23       Impact factor: 91.245

2.  Dietary intervention in infancy and later signs of beta-cell autoimmunity.

Authors:  Mikael Knip; Suvi M Virtanen; Karri Seppä; Jorma Ilonen; Erkki Savilahti; Outi Vaarala; Antti Reunanen; Kari Teramo; Anu-Maaria Hämäläinen; Johanna Paronen; Hans-Michael Dosch; Timo Hakulinen; Hans K Akerblom
Journal:  N Engl J Med       Date:  2010-11-11       Impact factor: 91.245

3.  Transient Epstein-Barr virus reactivation in CD3 monoclonal antibody-treated patients.

Authors:  Bart Keymeulen; Sophie Candon; Samira Fafi-Kremer; Anette Ziegler; Marianne Leruez-Ville; Chantal Mathieu; Evy Vandemeulebroucke; Markus Walter; Laurent Crenier; Eric Thervet; Christophe Legendre; Denis Pierard; Geoff Hale; Herman Waldmann; Jean-François Bach; Jean Marie Seigneurin; Daniel Pipeleers; Lucienne Chatenoud
Journal:  Blood       Date:  2009-12-09       Impact factor: 22.113

4.  Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass.

Authors:  B Keymeulen; M Walter; C Mathieu; L Kaufman; F Gorus; R Hilbrands; E Vandemeulebroucke; U Van de Velde; L Crenier; C De Block; S Candon; H Waldmann; A G Ziegler; L Chatenoud; D Pipeleers
Journal:  Diabetologia       Date:  2010-01-14       Impact factor: 10.122

5.  Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs β-cell function.

Authors:  S Alice Long; Mary Rieck; Srinath Sanda; Jennifer B Bollyky; Peter L Samuels; Robin Goland; Andrew Ahmann; Alex Rabinovitch; Sudeepta Aggarwal; Deborah Phippard; Laurence A Turka; Mario R Ehlers; Peter J Bianchine; Karen D Boyle; Steven A Adah; Jeffrey A Bluestone; Jane H Buckner; Carla J Greenbaum
Journal:  Diabetes       Date:  2012-06-20       Impact factor: 9.461
  5 in total
  1 in total

1.  Loss of intra-islet heparan sulfate is a highly sensitive marker of type 1 diabetes progression in humans.

Authors:  Charmaine J Simeonovic; Sarah K Popp; Lora M Starrs; Debra J Brown; Andrew F Ziolkowski; Barbara Ludwig; Stefan R Bornstein; J Dennis Wilson; Alberto Pugliese; Thomas W H Kay; Helen E Thomas; Thomas Loudovaris; Fui Jiun Choong; Craig Freeman; Christopher R Parish
Journal:  PLoS One       Date:  2018-02-07       Impact factor: 3.240
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.